Matches in Wikidata for { <http://www.wikidata.org/entity/Q86250484> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q86250484 description "clinical trial" @default.
- Q86250484 description "ensayu clínicu" @default.
- Q86250484 description "klinisch onderzoek" @default.
- Q86250484 description "клінічне випробування" @default.
- Q86250484 description "կլինիկական փորձարկում" @default.
- Q86250484 name "A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD)" @default.
- Q86250484 name "A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD)" @default.
- Q86250484 type Item @default.
- Q86250484 label "A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD)" @default.
- Q86250484 label "A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD)" @default.
- Q86250484 prefLabel "A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD)" @default.
- Q86250484 prefLabel "A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD)" @default.
- Q86250484 P1050 Q86250484-ABEBDAAF-6F8C-4F14-B145-6CCDD69AF313 @default.
- Q86250484 P1132 Q86250484-91E24F21-EDE5-4465-88CF-1928A4C34CDB @default.
- Q86250484 P1476 Q86250484-0C8209A2-1405-420F-AB9D-9CA71328D9B5 @default.
- Q86250484 P2899 Q86250484-55B02B4D-04EB-4C70-9527-8D2AFC55D6BA @default.
- Q86250484 P3098 Q86250484-56377367-30CC-48C7-8533-6AF977EC580A @default.
- Q86250484 P31 Q86250484-E8418524-58C7-4EA2-BDAF-0A602C09956D @default.
- Q86250484 P4844 Q86250484-04EB21CF-8DDF-48F1-8137-32D242C02C8D @default.
- Q86250484 P4844 Q86250484-18493714-241C-479C-AD2A-A0C062AB422C @default.
- Q86250484 P4844 Q86250484-2E23C2F7-33AF-419B-8BFF-C89C26125195 @default.
- Q86250484 P4844 Q86250484-4A146735-7CA2-4816-A507-A04A2AF4B7B2 @default.
- Q86250484 P580 Q86250484-4160B9AF-09F6-48DC-B7D8-F12776AF5B32 @default.
- Q86250484 P582 Q86250484-A9592043-9B91-4B82-9665-D1AD541675CA @default.
- Q86250484 P6099 Q86250484-ECFB06B2-A883-4A91-B8B2-DEBB2E6F9CF6 @default.
- Q86250484 P767 Q86250484-D9E8A32F-6617-40A0-82B4-C64B2FBA7E05 @default.
- Q86250484 P8363 Q86250484-B8C775E2-DA50-4B36-A143-D436F85FA849 @default.
- Q86250484 P921 Q86250484-1207C1A8-8957-4974-B0E6-A88BE04EAB1F @default.
- Q86250484 P1050 Q467635 @default.
- Q86250484 P1132 "+20" @default.
- Q86250484 P1476 "A Phase 2A Multi Centre, Open Label, Pilot Study Of Pembrolizumab Added to The Standard First-Line Therapy Of Cyclophosphamide, Bortezomib And Dexamethasone (CyBorD) In Newly Diagnosed Multiple Myeloma Patients Not Eligible For Autologous Stem Cell Transplantation" @default.
- Q86250484 P2899 "+18" @default.
- Q86250484 P3098 "NCT04258683" @default.
- Q86250484 P31 Q30612 @default.
- Q86250484 P4844 Q13896859 @default.
- Q86250484 P4844 Q15889608 @default.
- Q86250484 P4844 Q408524 @default.
- Q86250484 P4844 Q419319 @default.
- Q86250484 P580 "2020-03-01T00:00:00Z" @default.
- Q86250484 P582 "2023-11-01T00:00:00Z" @default.
- Q86250484 P6099 Q42824440 @default.
- Q86250484 P767 Q58219685 @default.
- Q86250484 P8363 Q78089383 @default.
- Q86250484 P921 Q188724 @default.